[go: up one dir, main page]

DK2089425T3 - Antiangiogene forbindelser - Google Patents

Antiangiogene forbindelser

Info

Publication number
DK2089425T3
DK2089425T3 DK07827123.6T DK07827123T DK2089425T3 DK 2089425 T3 DK2089425 T3 DK 2089425T3 DK 07827123 T DK07827123 T DK 07827123T DK 2089425 T3 DK2089425 T3 DK 2089425T3
Authority
DK
Denmark
Prior art keywords
compounds
antiangiogenic compounds
targeting
antibody
linked
Prior art date
Application number
DK07827123.6T
Other languages
English (en)
Inventor
Abhijit Bhat
Jing-Yu Lai
Venkata Doppalapudi
Dingguo Liu
Curt Bradshaw
Original Assignee
Covx Technologies Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Covx Technologies Ireland Ltd filed Critical Covx Technologies Ireland Ltd
Application granted granted Critical
Publication of DK2089425T3 publication Critical patent/DK2089425T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK07827123.6T 2006-11-10 2007-11-12 Antiangiogene forbindelser DK2089425T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86536006P 2006-11-10 2006-11-10
US93983007P 2007-05-23 2007-05-23
US94532907P 2007-06-20 2007-06-20
PCT/IE2007/000110 WO2008056346A2 (en) 2006-11-10 2007-11-12 Anti-angiogenic compounds

Publications (1)

Publication Number Publication Date
DK2089425T3 true DK2089425T3 (da) 2011-10-10

Family

ID=39364902

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07827123.6T DK2089425T3 (da) 2006-11-10 2007-11-12 Antiangiogene forbindelser

Country Status (18)

Country Link
US (3) US8288349B2 (da)
EP (2) EP2089425B1 (da)
JP (2) JP4897050B2 (da)
KR (2) KR20120043028A (da)
CN (1) CN101611053B (da)
AT (1) ATE520712T1 (da)
AU (1) AU2007318912B2 (da)
BR (1) BRPI0718591A2 (da)
CA (1) CA2669207A1 (da)
DK (1) DK2089425T3 (da)
IL (1) IL198581A (da)
MX (1) MX2009005045A (da)
MY (1) MY146985A (da)
NO (1) NO20092203L (da)
NZ (1) NZ576751A (da)
PL (1) PL2089425T3 (da)
PT (1) PT2089425E (da)
WO (1) WO2008056346A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2089425T3 (da) * 2006-11-10 2011-10-10 Covx Technologies Ireland Ltd Antiangiogene forbindelser
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
US8293714B2 (en) * 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
WO2010036930A1 (en) * 2008-09-26 2010-04-01 Javad Parvizi Methods and kits for detecting joint infection
KR20130050966A (ko) * 2010-07-12 2013-05-16 씨오브이엑스 테크놀로지스 아일랜드 리미티드 다기능적 항체 접합체
CA2815967A1 (en) * 2010-11-05 2012-05-10 Covx Technologies Ireland Limited Anti-diabetic compounds
EP2726088B1 (en) 2011-06-29 2019-01-02 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
WO2013093705A2 (en) * 2011-12-20 2013-06-27 Pfizer Inc. Improved processes for preparing peptide conjugates and linkers
US20130323234A1 (en) * 2012-01-09 2013-12-05 Covx Technologies Ireland Limited Mutant antibodies and conjugation thereof
MX350202B (es) 2012-03-28 2017-08-30 Amgen Inc Combinaciones de agonistas de receptores de muerte 5 (dr5).
EP3007717B1 (en) 2013-06-12 2018-08-29 Pharis Biotec GmbH Peptides with antagonistic activities against natural cxcr4
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
CA2921707C (en) * 2013-10-15 2023-03-28 Seattle Genetics, Inc. Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
US20190004048A1 (en) 2015-06-26 2019-01-03 Amgen Inc. Biomarker of Survival in the Treatment of Renal Cell Carcinoma with a VEGFR Inhibitor and an Ang2 Inhibitor
ES2919323T3 (es) 2015-12-04 2022-07-26 Seagen Inc Conjugados de compuestos de tubulisina cuaternizados
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
MA43835A (fr) 2016-03-25 2018-11-28 Seattle Genetics Inc Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires
ES2963839T3 (es) 2017-02-08 2024-04-02 Bristol Myers Squibb Co Polipéptidos de relaxina modificados que comprenden un potenciador farmacocinético y usos de los mismos
CA3056134A1 (en) 2017-03-24 2018-09-27 Seattle Genetics, Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
EP3617235A4 (en) 2017-04-28 2020-12-16 Ajinomoto Co., Inc. COMPOUND CONTAINING A SUBSTANCE HAVING AFFINITY FOR A SOLUBLE PROTEIN, CLIVABLE FRACTION, AND REACTIVE GROUP, OR SALT OF THE SAME

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5216132A (en) 1990-01-12 1993-06-01 Protein Design Labs, Inc. Soluble t-cell antigen receptor chimeric antigens
AU660926B2 (en) 1990-04-06 1995-07-13 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6080840A (en) 1992-01-17 2000-06-27 Slanetz; Alfred E. Soluble T cell receptors
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5733757A (en) 1995-12-15 1998-03-31 The Scripps Research Institute Aldolase catalytic antibody
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6326176B1 (en) 1997-12-18 2001-12-04 The Scripps Research Institute Aldol condensations by catalytic antibodies
JP2003516121A (ja) 1999-09-27 2003-05-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 不可逆的に結合するエンジニアリング抗体
US6294374B1 (en) 1999-10-08 2001-09-25 The Scripps Research Institute Use of catalytic antibodies for synthesizing epothilone
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
US20030045477A1 (en) 2001-07-26 2003-03-06 Fortuna Haviv Peptides having antiangiogenic activity
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
KR20040058229A (ko) * 2001-10-22 2004-07-03 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
US6737524B2 (en) * 2002-03-25 2004-05-18 Paul K. Smith Activated polyethylene glycol compounds
DE60305919T2 (de) 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US8143380B2 (en) 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
US7442778B2 (en) * 2004-09-24 2008-10-28 Amgen Inc. Modified Fc molecules
DK2089425T3 (da) * 2006-11-10 2011-10-10 Covx Technologies Ireland Ltd Antiangiogene forbindelser

Also Published As

Publication number Publication date
US20120301431A1 (en) 2012-11-29
EP2089425A2 (en) 2009-08-19
PT2089425E (pt) 2011-10-17
NO20092203L (no) 2009-08-10
BRPI0718591A2 (pt) 2013-12-03
KR101309948B1 (ko) 2013-09-23
KR20090090331A (ko) 2009-08-25
JP4897050B2 (ja) 2012-03-14
US8912148B2 (en) 2014-12-16
US8288349B2 (en) 2012-10-16
US20080166364A1 (en) 2008-07-10
NZ576751A (en) 2011-10-28
JP2012121886A (ja) 2012-06-28
WO2008056346B1 (en) 2008-12-04
CN101611053B (zh) 2015-06-03
CA2669207A1 (en) 2008-05-15
AU2007318912A1 (en) 2008-05-15
WO2008056346A2 (en) 2008-05-15
US20150057431A1 (en) 2015-02-26
IL198581A0 (en) 2011-08-01
KR20120043028A (ko) 2012-05-03
PL2089425T3 (pl) 2012-02-29
EP2089425B1 (en) 2011-08-17
ATE520712T1 (de) 2011-09-15
MX2009005045A (es) 2009-11-10
EP2368908A2 (en) 2011-09-28
IL198581A (en) 2015-10-29
EP2368908A3 (en) 2011-10-12
WO2008056346A3 (en) 2008-10-23
JP2010509315A (ja) 2010-03-25
AU2007318912B2 (en) 2011-03-03
MY146985A (en) 2012-10-15
CN101611053A (zh) 2009-12-23

Similar Documents

Publication Publication Date Title
DK2089425T3 (da) Antiangiogene forbindelser
WO2006094269A3 (en) Anti-angiogenic compounds
DOP2012000038A (es) Conjugados de dímeros de pirrolo [1,4] benzodiazepina como agentes anticancerosos
MX2009007146A (es) Conjugados porcion del factor ix-polimero que tienen ligadura que se puede liberar.
HN2006000668A (es) Compuestos de quinolina heteroaromaticos
WO2009051670A3 (en) Oxylipin compounds for the treatment of ophthalmic conditions
WO2009036175A3 (en) F1f0-atpase inhibitors and related methods
CR20140316A (es) Derivados de indol como antagonistas receptores de s1p1 (divisional 10922)
SE0202241D0 (sv) Novel Compounds
EA201200486A1 (ru) Лечение онкологических заболеваний
WO2008070129A3 (en) Compositions and methods for the treatment of inflammatory disease
WO2007138282A3 (en) Bi-aryl or aryl-heteroaryl substituted indoles
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
GB2466912A (en) Compositions and methods for treating lysosomal disorders
EA201270049A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
EA201170699A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
EA201170640A1 (ru) Дизамещенные фталазины-антагонисты сигнального пути hedgehog
NO20074047L (no) Ny fremgangsmate for fremstilling av substituerte indoler
DK1900362T3 (da) Alfa-aminoamidderivater anvendelige ved behandlingen af addiktive forstyrrelser
EA201170700A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
ATE430148T1 (de) Neue pyrrolodihydroisochinoline als pde10- inhibitoren
WO2010077310A3 (en) Amide derivatives of ethacrynic acid
UA110332C2 (en) Use of 2,3-dihydroxypropyldodecanoate for treatment of seborrhea
EA201001828A1 (ru) Способ синтеза производных 3,6-дигидро-1,3,5-триазина
BRPI0606783A2 (pt) derivados de imidazol